<DOC>
	<DOCNO>NCT00063999</DOCNO>
	<brief_summary>This randomized phase III trial compare well two different combination chemotherapy regimen ( doxorubicin hydrochloride , cisplatin , paclitaxel versus carboplatin paclitaxel ) work treat patient endometrial cancer stage III-IV come back ( recurrent ) . Drugs use chemotherapy doxorubicin hydrochloride , cisplatin , paclitaxel , carboplatin , work different way stop growth tumor cell , either kill cell , stop dividing , stop spread . It yet know combination chemotherapy regimen effective treat endometrial cancer .</brief_summary>
	<brief_title>Doxorubicin Hydrochloride , Cisplatin , Paclitaxel Carboplatin Paclitaxel Treating Patients With Stage III-IV Recurrent Endometrial Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine combination carboplatin paclitaxel ( TC ) chemotherapy therapeutically equivalent combination doxorubicin ( doxorubicin hydrochloride ) , cisplatin paclitaxel ( TAP ) chemotherapy regard survival . II . To determine estrogen/progesterone receptor status provide prognostic information patient treat chemotherapy . III . To assess whether combination TC chemotherapy superior combination TAP chemotherapy regard toxicity profile , specifically neurotoxicity infection . IV . To measure difference patient-reported neurotoxicity quality life ( QOL ) among regimen . OUTLINE : Patients randomize 1 2 treatment arm . Patients leave ventricular ejection fraction &lt; 50 % randomization initially randomize Arm I immediately cross Arm II . ARM I : Patients receive doxorubicin hydrochloride intravenously ( IV ) approximately 15-30 minute day 1 , cisplatin IV 60-90 minute day 1 , paclitaxel IV 3 hour day 2 , filgrastim subcutaneously ( SC ) day 3-12 pegfilgrastim SC day 3 . ARM II : Patients receive paclitaxel IV 3 hour carboplatin IV 30-60 minute day 1 . In arm , treatment repeat every 21 day 7 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month 2 year , every 6 month 3 year , annually thereafter .</detailed_description>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Uterine Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Succinylcholine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Patients must primary stage III stage IV recurrent endometrial carcinoma whose potential cure radiation therapy surgery alone combination poor ; pathological confirmation estrogen receptor ( ER ) /progesterone receptor ( PR ) status primary tumor mandatory ; however , result need available prior registration Patients may receive prior cytotoxic chemotherapy , include chemotherapy use radiation sensitization ; patient may receive prior radiation therapy , hormonal therapy , therapy biologic agent , therapy must discontinue prior entry study Patients radiation chemotherapy plan must receive radiation prior entry study ; least four week elapse since completion radiation therapy ( RT ) involve whole pelvis 50 % spine Platelets &gt; = 100,000/mcl Granulocytes ( absolute neutrophil count [ ANC ] ) &gt; = 1,500/mcl Creatinine = &lt; upper limit normal ( ULN ) ( Common Toxicity Criteria [ CTC ] grade 0 ) calculate creatinine clearance ( Jeliffe Formula ) &gt; = 60 ml/min Serum glutamate pyruvate transaminase ( SGPT ) ( alanine aminotransferase [ ALT ] ) = &lt; 3 x upper limit normal Bilirubin = &lt; institutional upper limit normal Patients must Gynecologic Oncology Group ( GOG ) performance status 0 , 1 , 2 Patients must meet preentry requirement Patients must sign approve informed consent authorization permit release personal health information Patients concomitant malignancy nonmelanoma skin cancer ; exception nonmelanoma skin cancer , patient prior invasive malignancy diseasefree &lt; 5 year receive prior chemotherapy malignancy Patients pathological confirmation estrogen receptor ( ER ) /progesterone receptor ( PR ) status tumor obtainable Patients radiation therapy plan study chemotherapy prior demonstrated progression Patients concomitant medical illness serious uncontrolled infection , uncontrolled angina , serious peripheral neuropathy , , opinion treat physician , make treatment prescribe study unreasonably hazardous patient Patients third degree complete heart block eligible unless pacemaker place ; patient medication alter cardiac conduction , digitalis , betablockers , calcium channel blocker , conduction abnormality cardiac dysfunction may place study discretion investigator Patients history myocardial infarct within 6 month enrollment , New York Heart Association ( NYHA ) class II great heart failure symptom suspicious congestive heart failure eligible unless left ventricular ejection fraction past 6 month document 50 % great ; patient leave ventricular ejection fraction ( LVEF ) ( perform reason ) less 50 % past 6 month ineligible Patients whose circumstance permit study completion adequate followup Patients sensitive E. coliderived drug preparation Patients uterine carcinosarcoma nonepithelial uterine malignancy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>